IFP Advisors’s Citius Oncology CTOR Stock Holding History

IFP Advisors’s Portfolio CTOR Stock Details CTOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.8K	Hold	107,424	–	–	﹤0.01%	2195
2026 Q1	$66.6K	Buy	107,424 +20,000	+23%	+$20.1K	﹤0.01%	2093
2025 Q4	$87.4K	Buy	87,424 +54,209	+163%	+$77.8K	﹤0.01%	1878
2025 Q3	$67.4K	Buy	33,215 +11,000	+50%	+$23.8K	﹤0.01%	1920
2025 Q2	$96.6K	Hold	22,215	–	–	﹤0.01%	1656
2025 Q1	$20.7K	Hold	22,215	–	–	﹤0.01%	2276
2024 Q4	$25.5K	Buy	22,215 +14,080	+173%	+$15.8K	﹤0.01%	2133
2024 Q3	$11.3K	Buy	+8,135	New	+$57.7K	﹤0.01%	2376

Other funds holding CTOR

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

IFP Advisors's CTOR Position: Q2 2026 in Review

IFP Advisors held its Citius Oncology (CTOR) position steady in Q2 2026 at 107,424 shares worth $69.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2195.

IFP Advisors first reported a position in CTOR in Q3 2024 and has held it in 8 quarters since. The position peaked at $96.6K in Q2 2025. 3 funds tracked by Wall St. Rank hold CTOR as of Q2 2026.

IFP Advisors held 107,424 shares of Citius Oncology worth $69.8K as of Q2 2026.
IFP Advisors left its Citius Oncology share count unchanged in Q2 2026.
Citius Oncology made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2195 holding.
IFP Advisors first reported a position in Citius Oncology in Q3 2024 and has held it in 8 quarters since.
IFP Advisors's Citius Oncology position peaked at $96.6K in Q2 2025.
3 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.